Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Xiang-Li Ning"'
Autor:
Guo-Bo Li, Gen Li, Ji Deng, Yang Lingling, Yu-Hang Yan, Xiang-Li Ning, Jun-Lin Yu, Qing-Qing Dai
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 11, Iss 7, Pp 1931-1946 (2021)
We herein describe AncPhore, a versatile tool for drug discovery, which is characterized by pharmacophore feature analysis and anchor pharmacophore (i.e., most important pharmacophore features) steered molecular fitting and virtual screening. Compara
Autor:
Ji Deng, Ze-Min Liu, Kai-Rong Zhu, Gui-Ling Cui, Lin-Xia Liu, Yu-Hang Yan, Xiang-Li Ning, Zhu-Jun Yu, Guo-Bo Li, Qing-Rong Qi
Publikováno v:
Bioorganic Chemistry. 135:106487
Autor:
Yong Wu, Ji Deng, Si-Yao Wang, Zong-Yuan Luo, Yali Ren, Yu-Xiang Wu, Cui Huo, Kai-Rong Zhu, Cheng Gao, Guo-Bo Li, Xiang-Li Ning, Jun-Lin Yu, Chen Yang, Shan Qian, Miao Wang, Gen Li, Zhouyu Wang, Cheng Peng, Yang Lingling, Yuzhi Li
Publikováno v:
Journal of medicinal chemistry. 64(12)
Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson's disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential effica
Autor:
Qing-Qing Dai, Yu-Hang Yan, Yu Su, Gen Li, Michael A. McDonough, Cheng Huang, Guo-Bo Li, Peng Jiayi, Xiang-Li Ning, Christopher J. Schofield, Chen Fu, Cheng-Long Zhu
Motivation Metalloenzymes are attractive targets for therapeutic intervention owing to their central roles in various biological processes and pathological situations. The fast-growing body of structural data on metalloenzyme-ligand interactions is f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3979763527ae00a83027753743115d9b
https://doi.org/10.1093/bioinformatics/btz648
https://doi.org/10.1093/bioinformatics/btz648
Autor:
Xiang-Li Ning, Zhao-Feng Li, Yubin Luo, Zhenling Wang, Guo Li, You-Cai Xiao, Ji Deng, Yu-Hang Yan, Jun-Lin Yu, Guo-Bo Li
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 41:127956
The production of β-lactamases represents the main cause of resistance to clinically important β-lactam antibiotics. Boron containing compounds have been demonstrated as promising broad-spectrum β-lactamase inhibitors to combat β-lactam resistanc